PEGylated Proteins Sales

PEGylated Proteins Sales Market Outlook

The global PEGylated proteins market is projected to reach approximately USD 9.3 billion by 2035, expanding at a robust compound annual growth rate (CAGR) of around 10.5% during the forecast period from 2025 to 2035. This growth trajectory is largely driven by the increasing prevalence of chronic diseases, advancements in drug delivery systems, and the rising demand for targeted therapy options in various healthcare applications. Additionally, the pharmaceutical industry's focus on innovative biologics and the growing need for improved pharmacokinetics and pharmacodynamics of therapeutic agents contribute significantly to the market's expansion. Furthermore, the enhanced stability and solubility offered by PEGylated proteins have made them a preferred choice for drug formulation, thereby fueling their adoption in various therapeutic areas.

Growth Factor of the Market

The PEGylated proteins market is witnessing substantial growth owing to several driving factors, including the surge in the incidence of cancer and autoimmune disorders that require effective therapeutic interventions. Enhanced drug efficacy, improved stability, and prolonged circulation time of PEGylated proteins have made them favorites among researchers and clinicians, thus increasing their acceptance in clinical practices. The pharmaceutical industry's shift towards biologics and the continued investment in research and development to discover novel PEGylated therapeutics further bolster market growth. Additionally, collaborations between biotech firms and pharmaceutical companies to advance PEGylation technologies and expand product portfolios contribute to the evolving landscape of this market. The growing number of active pipeline products and clinical trials also indicates a robust future for PEGylated proteins in the healthcare segment.

Key Highlights of the Market

• The global PEGylated proteins market is expected to grow at a CAGR of 10.5% from 2025 to 2035.
• Increased investment in research and development for innovative drug delivery mechanisms.
• Rising prevalence of chronic diseases and targeted therapies catalyzing market demand.
• Technological advancements enhancing the efficiency of PEGylation processes.
• Growing collaborations between pharmaceutical companies and biotech firms to develop novel PEGylated products.

By Product Type

PEGylated Enzymes:

PEGylated enzymes represent a significant segment within the market, offering enhanced therapeutic efficacy by improving the enzyme's stability and solubility in biological fluids. The PEGylation process helps reduce the immunogenic responses associated with these therapeutic agents, thereby prolonging their half-life and enhancing their bioavailability. This makes PEGylated enzymes particularly useful in the treatment of metabolic disorders, where enzyme replacement therapy is essential. Furthermore, the global shift towards personalized medicine and precision therapies is likely to spur further development and approval of PEGylated enzymes for various therapeutic applications, contributing to the growth of this segment.

PEGylated Antibodies:

PEGylated antibodies are pivotal in the PEGylated proteins market, primarily due to their application in targeted therapy for cancer and autoimmune diseases. The process of PEGylation significantly improves the pharmacokinetic properties of antibodies, allowing for extended circulation times in the bloodstream and minimizing the frequency of administration. As the demand for monoclonal antibodies continues to rise, the introduction of PEGylated alternatives is expected to enhance therapeutic profiles and patient compliance. This segment is poised for growth, particularly in the oncology space, where novel therapies are increasingly in demand to combat resistance and enhance treatment outcomes.

PEGylated Hormones:

PEGylated hormones are crucial in the management of various hormonal imbalances and disorders. The PEGylation process helps in prolonging the action of these hormones, thereby reducing the need for frequent dosing and improving patient adherence. For instance, PEGylated insulin formulations have emerged as a viable option for diabetes management, providing stable blood glucose control with fewer injections. The increasing incidence of metabolic disorders, coupled with the rising awareness of the benefits of PEGylated hormones, is expected to propel growth in this market segment significantly in the coming years.

PEGylated Cytokines:

PEGylated cytokines are gaining traction due to their ability to modulate immune responses in various diseases, including cancer and chronic inflammatory conditions. The PEGylation process enhances the stability and bioactivity of cytokines, allowing for improved therapeutic outcomes. As immunotherapy continues to evolve, the demand for PEGylated cytokines is anticipated to rise, especially in clinical settings where immune modulation is critical. The expanding research on the use of PEGylated cytokines in combination therapies further underscores their potential for growth within the market.

PEGylated Peptides:

PEGylated peptides have emerged as a promising class of therapeutics due to their ability to improve pharmacological properties, including solubility, stability, and half-life. The incorporation of PEG moieties significantly enhances the therapeutic potential of peptides, making them desirable candidates for various applications, including cancer treatment and metabolic disorders. As the market for peptide-based therapeutics continues to expand, the demand for PEGylated peptides is likely to grow as well, driven by advancements in peptide synthesis technologies and increasing investments in peptide drug discovery.

By Application

Cancer Treatment:

The application of PEGylated proteins in cancer treatment has witnessed a surge in adoption, primarily due to their ability to enhance drug delivery and reduce systemic toxicity associated with conventional chemotherapy. PEGylated agents facilitate targeted delivery to tumor sites, improving therapeutic efficacy while minimizing adverse effects on healthy tissues. This targeted approach is especially relevant in the development of new cancer therapies, as it aligns with the growing emphasis on personalized medicine. As research continues to unveil the potential of PEGylated proteins in oncology, the cancer treatment application segment is expected to experience significant growth.

Immune Disorders:

PEGylated proteins are increasingly being utilized in the treatment of immune disorders, primarily due to their enhanced bioavailability and reduced immunogenicity. Therapies incorporating PEGylated agents can modulate immune responses more effectively, thereby providing better management of autoimmune diseases and other related conditions. The rising prevalence of immune disorders globally has created a growing demand for innovative treatment options, which PEGylated proteins are well-positioned to fulfill. This segment's growth is anticipated to be driven by ongoing clinical research and the introduction of new therapies targeting immune-related diseases.

Blood Disorders:

The application of PEGylated proteins in the management of blood disorders is becoming increasingly prominent, particularly in the context of hemophilia and other coagulation deficiencies. PEGylated clotting factors offer improved pharmacokinetics, allowing for extended interval dosing and better patient compliance. As awareness around blood disorders rises and more patients seek effective treatments, the PEGylated proteins market is likely to see significant growth in this application segment. Advances in PEGylation technology are also expected to lead to the development of novel therapies that can further improve treatment outcomes for patients with blood disorders.

Chronic Diseases:

With the increasing prevalence of chronic diseases such as diabetes, cardiovascular diseases, and obesity, the application of PEGylated proteins in their management has gained substantial traction. PEGylation enhances the pharmacological profiles of therapeutic agents, enabling better management of these conditions through improved drug delivery and reduced side effects. As the global population ages and chronic diseases become more prevalent, the demand for PEGylated proteins in this application segment is poised to grow. Continuous innovation within this field aims to develop more effective and patient-friendly therapeutic options for managing chronic illnesses.

Others:

The "Others" segment encompasses various applications of PEGylated proteins across different therapeutic areas, including but not limited to genetic disorders and rare diseases. These applications are gaining recognition as advancements in PEGylation technology allow for the development of tailored therapies that meet specific patient needs. The ongoing research into novel indications for PEGylated proteins is expected to broaden their applications and further drive market growth. As healthcare systems aim to provide more comprehensive treatment options, the versatility of PEGylated proteins positions them well within this evolving landscape.

By Distribution Channel

Hospitals:

Hospitals serve as a critical distribution channel for PEGylated proteins, primarily because they house specialized medical professionals equipped to administer these advanced therapies. Hospital pharmacies are well-stocked with PEGylated products, ensuring that patients undergoing treatment for chronic diseases, cancers, and immune disorders have access to the latest therapies. The growing number of hospital admissions for chronic disease management is likely to drive the demand for PEGylated proteins through this channel. As healthcare systems continue to invest in advanced treatment capabilities, hospitals are expected to play a pivotal role in the distribution of PEGylated products.

Specialty Clinics:

Specialty clinics are increasingly becoming significant distribution channels for PEGylated proteins, particularly due to their focus on specific therapeutic areas such as oncology, immunology, and endocrinology. These clinics often provide specialized care and treatment plans tailored to the needs of their patients, making them ideal settings for administering PEGylated therapies. As the number of specialty clinics rises and the importance of personalized medicine grows, the market for PEGylated proteins through this channel is set to expand. The ability of specialty clinics to offer comprehensive management of complex conditions will further solidify their position as key distribution points for these advanced treatments.

Retail Pharmacies:

Retail pharmacies play a vital role in the distribution of PEGylated proteins, particularly for products that require less specialized handling. The convenience and accessibility of retail pharmacies cater to patients seeking ongoing management of their conditions with PEGylated medications. As the healthcare landscape evolves and more patients are prescribed PEGylated therapies for chronic illness management, retail pharmacies are likely to adapt their inventory to meet this growing demand. Enhanced patient awareness and education around PEGylated products will also contribute to increased sales through this distribution channel.

Online Pharmacies:

The rise of e-commerce has transformed the landscape for pharmaceutical distribution, and online pharmacies are becoming increasingly prominent in the sale of PEGylated proteins. The convenience of online purchasing combined with the discretion it offers to patients seeking treatment for chronic diseases and other health issues has led to a shift toward digital platforms. Online pharmacies provide a wider range of PEGylated medications and often feature competitive pricing and home delivery options, making them attractive to consumers. As technology and telehealth services continue to improve, the online pharmacy segment is expected to see significant growth within the PEGylated proteins market.

By Ingredient Type

Monomethoxy PEG:

Monomethoxy PEG is a widely used ingredient in the formulation of PEGylated proteins, favored for its ability to improve the solubility and stability of therapeutic agents. This ingredient is particularly beneficial for drugs that require a prolonged half-life and improved pharmacokinetics. The versatility of monomethoxy PEG allows it to be utilized in various applications ranging from cancer therapies to metabolic disorder treatments. As the demand for effective PEGylated products grows, the market for monomethoxy PEG is likely to expand, supported by ongoing research and development efforts in the field of biopharmaceuticals.

Methoxy PEG:

Methoxy PEG serves as an essential component in the PEGylation process, contributing to the improved performance of therapeutic proteins. Its ability to enhance the circulation time of biological agents makes it particularly valuable in oncology and chronic disease management. Methoxy PEG-based PEGylated products are increasingly being developed as they provide a favorable balance between efficacy and safety. As researchers explore innovative formulations utilizing methoxy PEG, this ingredient is expected to gain traction in the PEGylated proteins market, further emphasizing its importance in the development of advanced therapeutics.

Monoamine PEG:

Monoamine PEG has emerged as a promising ingredient in the development of PEGylated proteins, offering unique properties that can enhance therapeutic profiles. Its ability to provide increased hydrophilicity and lower immunogenicity makes monoamine PEG an attractive choice for researchers and formulators. This ingredient is particularly beneficial for peptides and proteins that require modification to improve their performance in clinical settings. As the demand for customized PEGylated therapies continues to rise, the market for monoamine PEG is anticipated to grow significantly, driven by advancements in formulation technologies and ongoing clinical trials.

Diacid PEG:

Diacid PEG is gaining popularity in the PEGylated proteins market due to its ability to create more complex structures that can stabilize therapeutic agents. Its unique properties enable the formation of cross-linked networks, which can improve drug delivery and release profiles. As researchers aim to develop advanced drug formulations that require enhanced stability and controlled release mechanisms, diacid PEG is expected to play a crucial role. This ingredient is particularly relevant in the context of cancer therapies and other applications where sustained therapeutic effects are essential.

Branched PEG:

Branched PEG is an innovative ingredient that offers enhanced solubility and therapeutic efficacy for PEGylated proteins. Its unique branched structure allows for improved functionalization and can significantly influence the pharmacokinetics of therapeutic agents. As the focus shifts towards developing more effective and tailored PEGylated solutions, branched PEG is likely to gain prominence. Researchers are increasingly exploring its potential in various therapeutic applications, which is expected to fuel growth in this segment of the PEGylated proteins market.

By Region

The regional analysis of the PEGylated proteins market reveals a dynamic landscape, with North America leading the way due to high healthcare expenditure, advanced healthcare infrastructure, and robust pharmaceutical research and development activities. The North American market is estimated to account for nearly 40% of the global market share, driven by the increasing prevalence of chronic diseases and a growing focus on biologic therapies. The CAGR for this region is projected to be around 11% over the forecast period, highlighting the sustained demand for advanced therapeutic options. In addition to strong market performance in the United States, Canada is also contributing to the growth of PEGylated proteins due to supportive government policies aimed at fostering innovation in drug development.

Europe is another significant contributor to the PEGylated proteins market, accounting for approximately 30% of the global market share. The European market is characterized by a well-established regulatory framework that promotes the development and commercialization of innovative therapeutics. The increasing incidence of immune disorders and blood disorders is driving the demand for PEGylated proteins in the region. Moreover, countries like Germany, France, and the UK are witnessing a surge in research activities focused on PEGylation technologies, which is expected to support growth in this region. The CAGR for the European market is projected to be around 9% during the forecast period, indicating steady growth driven by advancements in biotechnology and the expansion of therapeutic applications.

Opportunities

One of the major opportunities in the PEGylated proteins market lies in the ongoing advancements in biotechnology and pharmaceutical research. As scientists and researchers continue to explore new PEGylation techniques and novel therapeutic applications, there is significant potential for the development of innovative PEGylated products. The increasing focus on personalized medicine and targeted therapies is also creating new avenues for PEGylated proteins to address specific patient needs. Furthermore, as regulatory bodies become more supportive of advanced therapeutic modalities, there is an opportunity for faster approval times for PEGylated products, allowing companies to capitalize on emerging market demands more effectively.

Another opportunity exists in the expansion of global markets, particularly in emerging economies where healthcare systems are evolving rapidly. Regions such as Asia Pacific and Latin America are witnessing increased investments in biotechnology and pharmaceuticals, creating a growing demand for PEGylated proteins. As healthcare access improves and awareness of advanced therapies increases, these markets present significant growth potential. Companies that strategically position themselves in these emerging regions and tailor their offerings to meet local patient needs will likely gain a competitive advantage. With the increasing globalization of healthcare, collaborations and partnerships between local players and established pharmaceutical companies can further enhance market reach and foster innovation in PEGylated protein development.

Threats

Despite the numerous opportunities present in the PEGylated proteins market, several threats could hinder growth prospects. One primary concern is the potential for regulatory hurdles associated with the approval of new PEGylated therapeutics. The complex nature of these products often requires extensive clinical trials to demonstrate safety and efficacy, which can be time-consuming and costly. Additionally, the regulatory landscape varies significantly across different regions, posing challenges for companies seeking to market their products globally. Any changes in regulations or increased scrutiny from health authorities could slow down the introduction of new PEGylated products, affecting overall market growth.

Another significant threat to the PEGylated proteins market is the intense competition from alternative therapeutic modalities and biosimilars. As biotechnology advances, new treatment options are continually being developed, which could pose challenges to the market share of PEGylated proteins. Furthermore, the emergence of biosimilars—particularly for well-established PEGylated products—could lead to price erosion and reduced profitability for original developers. Companies must stay ahead of these competitive pressures through continuous innovation, effective marketing strategies, and robust intellectual property protection to safeguard their market positions.

Competitor Outlook

• Amgen Inc.
• PEGylated Therapeutics Inc.
• Merck KGaA
• Roche Holding AG
• Sobi (Swedish Orphan Biovitrum AB)
• Polaris Pharmaceuticals
• F. Hoffmann-La Roche AG
• Pfizer Inc.
• Vivia Biotech
• AbbVie Inc.
• Takeda Pharmaceutical Company Limited
• Novartis AG
• Sanofi S.A.
• Gilead Sciences, Inc.
• Fujifilm Diosynth Biotechnologies

The competitive landscape of the PEGylated proteins market is characterized by a diverse range of players operating across various segments. Established pharmaceutical companies are actively investing in research and development to expand their portfolios and enhance their PEGylation technologies. These companies are focused on collaborations and partnerships to leverage their strengths and accelerate the commercialization of novel PEGylated agents. The market is also witnessing the emergence of biotech firms specializing in PEGylation processes, which are developing innovative therapies targeting specific diseases, further intensifying competition. Overall, the PEGylated proteins market remains highly competitive, driven by the need for effective therapeutics and tailored treatment options.

Major companies like Amgen Inc., Roche Holding AG, and Pfizer Inc. hold significant market positions due to their extensive experience and established product lines. Amgen, for instance, has successfully developed PEGylated formulations for treating various chronic conditions, showcasing its commitment to innovation in the biopharmaceutical space. Roche, with its strong focus on oncology and immunotherapy, has also made significant strides in the development of PEGylated proteins, aiming to enhance therapeutic efficacy and patient outcomes. Meanwhile, Pfizer is leveraging its global reach and resources to advance its PEGylated product offerings, actively participating in clinical trials to bring new therapies to market.

Emerging companies such as PEGylated Therapeutics Inc. and Polaris Pharmaceuticals are also making their mark in the PEGylated proteins space, focusing on niche therapeutic areas and innovative drug delivery systems. Their agility and adaptability allow them to respond quickly to market demands and explore new opportunities in PEGylation technology. With ongoing advancements in biotechnology and increasing investments in research, these smaller players could potentially disrupt the market dynamics and contribute to the evolution of PEGylated therapeutics. The competitive landscape is thus characterized by both established giants and innovative newcomers working towards similar goals of improving patient care through advanced PEGylated products.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Amgen Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Merck KGaA
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 AbbVie Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Novartis AG
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Pfizer Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Sanofi S.A.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Vivia Biotech
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Roche Holding AG
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Gilead Sciences, Inc.
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 F. Hoffmann-La Roche AG
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Polaris Pharmaceuticals
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 PEGylated Therapeutics Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Fujifilm Diosynth Biotechnologies
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Sobi (Swedish Orphan Biovitrum AB)
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Takeda Pharmaceutical Company Limited
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 PEGylated Proteins Sales Market, By Application
    • 6.1.1 Cancer Treatment
    • 6.1.2 Immune Disorders
    • 6.1.3 Blood Disorders
    • 6.1.4 Chronic Diseases
    • 6.1.5 Others
  • 6.2 PEGylated Proteins Sales Market, By Ingredient Type
    • 6.2.1 Monomethoxy PEG
    • 6.2.2 Methoxy PEG
    • 6.2.3 Monoamine PEG
    • 6.2.4 Diacid PEG
    • 6.2.5 Branched PEG
  • 6.3 PEGylated Proteins Sales Market, By Distribution Channel
    • 6.3.1 Hospitals
    • 6.3.2 Specialty Clinics
    • 6.3.3 Retail Pharmacies
    • 6.3.4 Online Pharmacies

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 PEGylated Proteins Sales Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global PEGylated Proteins Sales market is categorized based on

By Application

• Cancer Treatment
• Immune Disorders
• Blood Disorders
• Chronic Diseases
• Others

By Distribution Channel

• Hospitals
• Specialty Clinics
• Retail Pharmacies
• Online Pharmacies

By Ingredient Type

• Monomethoxy PEG
• Methoxy PEG
• Monoamine PEG
• Diacid PEG
• Branched PEG

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Amgen Inc.
• PEGylated Therapeutics Inc.
• Merck KGaA
• Roche Holding AG
• Sobi (Swedish Orphan Biovitrum AB)
• Polaris Pharmaceuticals
• F. Hoffmann-La Roche AG
• Pfizer Inc.
• Vivia Biotech
• AbbVie Inc.
• Takeda Pharmaceutical Company Limited
• Novartis AG
• Sanofi S.A.
• Gilead Sciences, Inc.
• Fujifilm Diosynth Biotechnologies